scholarly journals Immunohistochemical Coexpression of Epithelial Cell Adhesion Molecule and Alpha-Fetoprotein in Hepatocellular Carcinoma

2018 ◽  
Vol 2018 ◽  
pp. 1-8
Author(s):  
Leonardo do Prado Lima ◽  
Carla Jorge Machado ◽  
João Bernardo Sancio Rocha Rodrigues ◽  
Leonardo de Souza Vasconcellos ◽  
Eduardo Paulino Junior ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Adhesion ◽  
Epithelial Cell ◽  
Adhesion Molecule ◽  
Cell Adhesion Molecule ◽  
Univariate Analysis ◽  
Alpha Fetoprotein ◽  
Epithelial Cell Adhesion Molecule ◽  
Number Of Patients ◽  
Significant Difference

Background and Aim. The epithelial cell adhesion molecule (EpCAM) has been proposed as a marker for cancer stem cells in human hepatocellular carcinoma (HCC) as well as in the development of novel target therapies. This study aimed to investigate the immunohistochemical expression of EpCAM and alpha-fetoprotein (AFP) in HCC patients and their association with clinicopathological characteristics. Methods. This study included Child-Pugh A HCC patients undergoing curative surgical resection. Results. A significant difference was observed in the ratio between the different phenotypes (p = 0.002), identifying 12 (29.3%) EPCAM positive tumors and 29 (70.7%) negative tumors. EpCAM+ expression was associated with AFP + (OR = 12.5, 95% CI, 1.9-84.1, p<0.001). In univariate analysis, a significant association was observed between AFP+ and EPCAM+ and the serum AFP level. A diameter of ≤ 5 cm was associated with EPCAM+, while angiolymphatic invasion was associated with APF+. In a multivariate analysis, only tumors of ≤ 5 cm were significantly associated with EpCAM+ (OR = 8.7; 95%CI, 1.27-100.0; p = 0.022). The overall survival rate was 74.9%, 69.4%, 69.4%, and 53.5% at 12, 24, 36, and 48 months, respectively. Conclusion. A considerable number of patients with EpCAM+ HCC would benefit from a specific target therapy.

scholarly journals Expression and role of epithelial cell adhesion molecule in dysplastic nodule and hepatocellular carcinoma

2012 ◽  
Vol 41 (6) ◽  
pp. 2150-2158 ◽  
Author(s):  
JUN SANG BAE ◽  
SANG JAE NOH ◽  
KYU YUN JANG ◽  
HO SUNG PARK ◽  
MYOUNG JA CHUNG ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Adhesion ◽  
Epithelial Cell ◽  
Adhesion Molecule ◽  
Cell Adhesion Molecule ◽  
Dysplastic Nodule ◽  
Epithelial Cell Adhesion Molecule

scholarly journals Identification of microRNAs specific for epithelial cell adhesion molecule-positive tumor cells in hepatocellular carcinoma

Hepatology ◽  
2015 ◽  
Vol 62 (3) ◽  
pp. 829-840 ◽  
Author(s):  
Junfang Ji ◽  
Xin Zheng ◽  
Marshonna Forgues ◽  
Taro Yamashita ◽  
Eliane L. Wauthier ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Adhesion ◽  
Epithelial Cell ◽  
Tumor Cells ◽  
Adhesion Molecule ◽  
Cell Adhesion Molecule ◽  
Epithelial Cell Adhesion Molecule

scholarly journals Reduction in membranous immunohistochemical staining for the intracellular domain of epithelial cell adhesion molecule correlates with poor patient outcome in primary colorectal adenocarcinoma

2016 ◽  
Vol 23 (3) ◽  
pp. 171 ◽  
Author(s):  
A. Wang ◽  
R. Ramjeesingh ◽  
C.H. Chen ◽  
D. Hurlbut ◽  
N. Hammad ◽  
...  
Keyword(s):  
Cell Adhesion ◽  
Epithelial Cell ◽  
Adhesion Molecule ◽  
Immunohistochemical Staining ◽  
Cell Adhesion Molecule ◽  
Colorectal Adenocarcinoma ◽  
Univariate Analysis ◽  
Lymph Node Status ◽  
Epithelial Cell Adhesion Molecule ◽  
Intracellular Domain

Background Epithelial cell adhesion molecule (EpCAM) is a multifunctional transmembrane glycoprotein expressed on both normal epithelium and epithelial neoplasms such as gastric, breast, and renal carcinomas. Recent studies have proposed that the proteolytic cleavage of the intracellular domain of EpCAM (EpCAM-ICD) can trigger signalling cascades leading to aggressive tumour behavior. The expression profile of EpCAM-ICD has not been elucidated for primary colorectal carcinoma. In the present study, we examined EpCAM-ICD immunohistochemical staining in a large cohort of patients with primary colorectal adenocarcinoma and assessed its performance as a potential prognostic marker.MethodsImmunohistochemical staining for EpCAM-ICD was assessed on tissue microarrays consisting of 137 primary colorectal adenocarcinoma samples. Intensity of staining for each core was scored by 3 independent pathologists. The membranous EpCAM-ICD staining score was calculated as a weighted average from 3 core samples per tumour. Univariate analysis of the average scores and clinical outcome measures was performed.Results The level of membranous EpCAM-ICD staining was positively associated with well-differentiated tumours (p = 0.01); low preoperative carcinoembryonic antigen (p = 0.001); and several measures of survival, including 2-year (p = 0.02) and 5-year survival (p = 0.05), and length of time post-diagnosis (p = 0.03). A number of other variables — including stage, grade, and lymph node status—showed correlations with EpCAM staining and markers of poor outcome, but did not reach statistical significance.ConclusionsLow membranous EpCAM-ICD staining might be a useful marker to identify tumours with aggressive clinical behavior and potential poor prognosis and might help to select candidates who could potentially benefit from treatment targeting EpCAM.

Sign in / Sign up

Export Citation Format

Share Document